Desloratadine, an FDA-approved Cationic Amphiphilic Drug, Inhibits SARS-CoV-2 Infection in Cell Culture and Primary Human Nasal Epithelial Cells by Blocking Viral Entry - Normandie Université Accéder directement au contenu
Article Dans Une Revue Scientific Reports Année : 2022

Desloratadine, an FDA-approved Cationic Amphiphilic Drug, Inhibits SARS-CoV-2 Infection in Cell Culture and Primary Human Nasal Epithelial Cells by Blocking Viral Entry

François Berry
  • Fonction : Auteur
Dennis Salomón López-Molina
  • Fonction : Auteur
Công Trung Nguyễn
  • Fonction : Auteur
Kevin Sereno
  • Fonction : Auteur

Résumé

The 2019 global coronavirus (COVID-19) pandemic has brought the world to a grinding halt, highlighting the urgent need for therapeutic and preventive solutions to slow the spread of emerging viruses. The objective of this study was to assess the anti-SARS-CoV-2 effectiveness of 8 FDA-approved cationic amphiphilic drugs (CADs). SARS-CoV-2-infected Vero cells, Calu-3 cells and primary Human Nasal Epithelial Cells (HNEC) were used to investigate the effects of CADs and revealed their antiviral mode of action. Among the CADs tested, desloratadine, a commonly used antiallergic, well-tolerated with no major side effects, potently reduced the production of SARS-CoV-2 RNA in Vero-E6 cells. Interestingly, desloratadine was also effective against HCoV-229E and HCoV-OC43 showing that it possessed broad-spectrum anti-coronavirus activity. Investigation of its mode of action revealed that it targeted an early step of virus lifecycle and blocked SARS-CoV-2 entry through the endosomal pathway. Finally, the ex vivo kinetic of the antiviral effect of desloratadine was evaluated on primary Human Nasal Epithelial Cells (HNEC), showing a significant delay of viral RNA production with a maximal reduction reached after 72~h of treatment. Thus, this treatment could provide a substantial contribution to prophylaxis and systemic therapy of COVID-19 or other coronaviruses infections and requires further studies.
Fichier principal
Vignette du fichier
s41598-022-25399-5.pdf (3.09 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04420874 , version 1 (08-04-2024)

Identifiants

Citer

Margot Morin-Dewaele, Sophie Bartier, François Berry, Rozenn Brillet, Dennis Salomón López-Molina, et al.. Desloratadine, an FDA-approved Cationic Amphiphilic Drug, Inhibits SARS-CoV-2 Infection in Cell Culture and Primary Human Nasal Epithelial Cells by Blocking Viral Entry. Scientific Reports, 2022, 12 (1), pp.21053. ⟨10.1038/s41598-022-25399-5⟩. ⟨hal-04420874⟩
50 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More